Related Experiment Video
Updated: Aug 20, 2025
In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells
Published on: February 18, 2015
Regulatory T Cells in Ovarian Carcinogenesis and Future Therapeutic Opportunities
Emily Cassar1, Apriliana E R Kartikasari1, Magdalena Plebanski1
1School of Health and Biomedical Science, Royal Melbourne Institute of Technology, Bundoora, VIC 3083, Australia.
Abstract:
Regulatory T cells (Tregs) have been shown to play a role in the development of solid tumors. A better understanding of the biology of Tregs, immune suppression by Tregs, and how cancer developed with the activity of Tregs has facilitated the development of strategies used to improve immune-based therapy. In ovarian cancer, Tregs have been shown to promote cancer development and resistance at different cancer stages. Understanding the various Treg-mediated immune escape mechanisms provides opportunities to establish specific, efficient, long-lasting anti-tumor immunity. Here, we review the evidence of Treg involvement in various stages of ovarian cancer. We further provide an overview of the current and prospective therapeutic approaches that arise from the modulation of Treg-related tumor immunity at those specific stages. Finally, we propose combination strategies of Treg-related therapies with other anti-tumor therapies to improve clinical efficacy and overcome tumor resistance in ovarian cancer.
Insights
Regulatory T cells (Tregs) drive ovarian cancer progression and immune evasion. Targeting Tregs offers new strategies to enhance anti-tumor immunity and overcome treatment resistance in ovarian cancer patients.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Regulatory T cells (Tregs) are implicated in solid tumor development.
- Tregs play a crucial role in immune suppression within the tumor microenvironment.
- Understanding Treg biology is key to improving cancer immunotherapies.
Purpose of the Study:
- To review the role of Tregs in ovarian cancer progression across different stages.
- To overview current and future therapeutic strategies targeting Tregs in ovarian cancer.
- To propose combination therapies for enhanced clinical efficacy.
Main Methods:
- Literature review of Treg involvement in ovarian cancer.
- Analysis of Treg-mediated immune escape mechanisms.
- Evaluation of therapeutic approaches modulating Treg activity.
Main Results:
- Tregs promote ovarian cancer development and resistance at various stages.
- Treg-mediated immune suppression hinders effective anti-tumor responses.
- Targeting Tregs presents opportunities for novel ovarian cancer treatments.
Conclusions:
- Modulating Treg activity is a promising strategy for ovarian cancer immunotherapy.
- Combination therapies involving Treg modulation may overcome tumor resistance.
- Further research into Treg-specific targeting can improve patient outcomes.
